Lyra Therapeutics, Inc. (LYRA)
0.80
+0.10
(+14.29%)
USD |
OTCM |
Jun 09, 16:00
Lyra Therapeutics Enterprise Value : 15.79M for June 9, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 09, 2026 | 15.79M |
| June 08, 2026 | 15.61M |
| June 05, 2026 | 15.61M |
| June 04, 2026 | 15.60M |
| June 03, 2026 | 15.54M |
| June 02, 2026 | 15.61M |
| June 01, 2026 | 15.61M |
| May 29, 2026 | 15.68M |
| May 28, 2026 | 15.61M |
| May 27, 2026 | 15.40M |
| May 26, 2026 | 15.29M |
| May 22, 2026 | 15.36M |
| May 21, 2026 | 15.29M |
| May 20, 2026 | 15.33M |
| May 19, 2026 | 15.34M |
| May 18, 2026 | 15.23M |
| May 15, 2026 | 15.29M |
| May 14, 2026 | 15.36M |
| May 13, 2026 | 15.36M |
| May 12, 2026 | 15.33M |
| May 11, 2026 | 15.35M |
| May 08, 2026 | 15.33M |
| May 07, 2026 | 15.36M |
| May 06, 2026 | 15.33M |
| May 05, 2026 | 15.33M |
| Date | Value |
|---|---|
| May 04, 2026 | 15.36M |
| May 01, 2026 | 15.35M |
| April 30, 2026 | 15.30M |
| April 29, 2026 | 15.30M |
| April 28, 2026 | 15.31M |
| April 27, 2026 | 15.36M |
| April 24, 2026 | 15.31M |
| April 23, 2026 | 15.40M |
| April 22, 2026 | 15.37M |
| April 21, 2026 | 15.36M |
| April 20, 2026 | 15.35M |
| April 17, 2026 | 15.43M |
| April 16, 2026 | 15.24M |
| April 15, 2026 | 15.24M |
| April 14, 2026 | 15.24M |
| April 13, 2026 | 15.23M |
| April 10, 2026 | 15.23M |
| April 09, 2026 | 15.07M |
| April 08, 2026 | 15.03M |
| April 07, 2026 | 15.07M |
| April 06, 2026 | 15.02M |
| April 02, 2026 | 15.02M |
| April 01, 2026 | 15.02M |
| March 31, 2026 | 15.02M |
| March 30, 2026 | 15.02M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Filana Therapeutics, Inc. | -17.98M |
| CorMedix, Inc. | 644.26M |
| Eloxx Pharmaceuticals, Inc. | -1.291M |
| Cannabis Global, Inc. | -- |
| BioStem Technologies, Inc. | 50.12M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.951M |
| Revenue (Quarterly) | 0.007M |
| Total Expenses (Quarterly) | 6.958M |
| EPS Diluted (Quarterly) | -3.916 |
| Gross Profit Margin (Quarterly) | -1.33K% |
| Profit Margin (Quarterly) | -99.30K% |
| Earnings Yield | -1.62K% |
| Normalized Earnings Yield | -1582.05 |